Amanote Research
Register
Sign In
Cost-Effectiveness of Regular Utilization of Zoledronic Acid for Developed Bone Metastases From Advanced Breast Cancer in Chinese Patients
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.04.200
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
May 1, 2018
Authors
Y Cui
Q Zhang
W Zhang
M He
C Zhao
C Liu
J Qian
H Zhan
W Chen
W Zheng
Publisher
Elsevier BV
Related search
Economic Evaluation of Denosumab Compared With Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients With Bone Metastases
Journal of Managed Care Pharmacy
Cost-Effectiveness Analysis of Neoadjuvant Chemotherapy With Zoledronic Acid for HER2-Negative Breast Cancer in Japan: The JONIE1 Study
Health
Strategies for Treatment of Bone Metastases From Breast Cancer
Zoledronic Acid and Skeletal Complications in Patients With Solid Tumors and Bone Metastases
Cancer
Cancer Research
Oncology
PCN67 Cost Effectiveness of Zoledronic Acid (ZOL) in Postmenopausal Women With Early Breast Cancer Receiving Adjuvant Letrozole From German and Italian Perspectives
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Enhancing Quality of Life for Breast Cancer Patients With Bone Metastases
PCN66 Cost-Effectiveness of Denosumab Versus Zoledronic Acid for Skeletal-Related Event (SRE) Reduction in Bone-Metastatic Prostate Cancer (mPC) in the UK
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Analysis of Orthopedic Surgery of Bone Metastases in Breast Cancer Patients
BMC Musculoskeletal Disorders
Rheumatology
Orthopedics
Sports Medicine
Breast-Cancer Adjuvant Therapy With Zoledronic Acid
New England Journal of Medicine
Medicine
